PF-07976016 Formulations for Healthy Adults
Trial Summary
Do I have to stop taking my current medications?
Yes, you must stop taking prescription or non-prescription drugs within a specified timeframe before the study starts.
What data supports the idea that null (also known as: PF-07976016, PF 07976016) is an effective treatment?
The available research does not provide specific data supporting the effectiveness of null (PF-07976016) for its intended condition. The studies mentioned focus on other treatments and conditions, such as femoral neck fracture recovery, cancer therapy evaluation, pediatric intensive care outcomes, geriatric rehabilitation, and IVF stimulation regimens. Therefore, there is no direct evidence from these studies to support the effectiveness of null.12345
What safety data is available for the treatment PF-07976016?
Is the drug PF-07976016 a promising treatment?
What is the purpose of this trial?
The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This clinical trial is for healthy adults. Specific eligibility criteria are not provided, but typically participants should have no significant medical conditions and be within a certain age range.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of PF-07976016 in up to 3 study periods with a 7-day washout period between doses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PF-07976016
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University